Company news

PDS Biotechnology Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results

May 10, 2022

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results

April 27, 2022

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

April 26, 2022

PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

April 18, 2022

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results

March 30, 2022

PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

March 21, 2022

PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers

March 14, 2022

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results

March 8, 2022

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

February 23, 2022

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

February 14, 2022

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

February 1, 2022

PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

January 26, 2022

PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

January 11, 2022

PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

January 9, 2022

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

December 22, 2021

PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

December 5, 2021

PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results

November 9, 2021

PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute

November 7, 2021

PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine

October 31, 2021

PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

October 20, 2021

PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results

October 12, 2021

PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer

October 5, 2021

PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer

October 3, 2021

PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer

September 19, 2021

PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

September 8, 2021

PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results

August 11, 2021

PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences

July 27, 2021

PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

July 25, 2021

PDS Biotechnology Joins Russell Microcap® Index

June 30, 2021

PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

June 16, 2021

PDS Biotech Prices Public Offering of Common Stock

June 14, 2021

PDS Biotech Announces Proposed Offering of Common Stock

June 13, 2021

PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting

June 7, 2021

PDS Biotechnology Set to Join Russell Microcap® Index

June 6, 2021

PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors

June 2, 2021

PDS Biotech to Host Oncology R&D Day on June 16, 2021

May 31, 2021

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

May 26, 2021

PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting

May 23, 2021

PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

May 19, 2021

PDS Biotechnology Appoints Immuno-Oncology Experts Dr. Olivera Finn and Dr. Mark Frohlich to Scientific Advisory Board

May 17, 2021

PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results

May 12, 2021

PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Clinical Oncology Annual Meeting

April 28, 2021

PDS Biotechnology Announces Conference Call and Webcast for First Quarter Financial Results

April 25, 2021

PDS Biotech Reports Financial Results for the Year Ended December 31, 2020 and Provides Business Update

March 17, 2021

PDS Biotech Announces Presentation and Panel Participation at the Benzinga Biotech Small Cap Conference

March 16, 2021

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2020 Financial Results

March 7, 2021

PDS Biotech Announces Presentations in Upcoming Healthcare Investor Conferences

March 2, 2021

PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine

February 21, 2021

PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute

February 2, 2021

PDS Biotech Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference

January 4, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 75 decks. Every deck is listed under its year.